Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
Pfizer sells off partial stake in Haleon, potentially raising $2B+
Last year
Deals
GSK’s new PhIII data support bid for wider endometrial cancer label for Jemperli
Last year
R&D
Updated: FDA adcomm backs benefits of Abecma and Carvykti in earlier patients
Last year
FDA+
Moderna turns the spotlight on long Covid with new initiatives
Last year
Coronavirus
Marketing
Bristol Myers scores accelerated approval in more blood cancers for CAR-T therapy Breyanzi
Last year
Cell/Gene Tx
FDA+
FDA lays out cross-agency efforts on regulating AI in medical products
Last year
AI
FDA+
After years of delay, BeiGene finally lands FDA approval for its PD-1 drug
Last year
China
FDA+
FDA adcomm votes in favor of Geron's anemia drug for cancer patients despite questions on risk
Last year
FDA+
FDA approves Madrigal’s NASH drug, marking the first-ever treatment for the liver disease
Last year
FDA+
European Parliament to dig into pharma legislative revision next week
Last year
Pharma mass-market TV advertising fading in favor of personalized media, agency says
Last year
Marketing
Lawmakers amp up calls for PBM reforms to be included in next week's funding package
Last year
FDA+
UK's NICE says it's not ready to recommend Vertex's Casgevy for sickle cell
Last year
Cell/Gene Tx
Mirum expands label for rare liver disease drug, serving up more competition for Ipsen's Bylvay
Last year
FDA+
BIO to cut ties with WuXi after trade group was accused of acting as a foreign agent
Last year
China
FDA raises concerns of 'early deaths' in Abecma and Carvykti multiple myeloma trials
Last year
FDA+
Alnylam takes a family road trip to talk about health history and heredity in new rare disease campaign
Last year
Marketing
Federal appeals court rules in favor of Arkansas in PhRMA's suit over 340B expansion
Last year
Law
Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds
Last year
Marketing
Eli Lilly CEO David Ricks talks China, AI, and pharma's next 'golden era' after obesity
Last year
Novartis returns for another piece of IFM Therapeutics
Last year
Deals
FDA challenges safety, efficacy of Geron's imetelstat ahead of advisory committee meeting
Last year
FDA+
Madrigal to grapple with lack of awareness about NASH ahead of potential FDA approval
Last year
Marketing
US spent $3B on DMD treatments as confirmatory studies still underway, JAMA paper says
Last year
FDA+
First page
Previous page
67
68
69
70
71
72
73
Next page
Last page
